Sysmex Corporation (SSMXF)

OTCMKTS · Delayed Price · Currency is USD
13.30
0.00 (0.00%)
Aug 24, 2025, 8:00 PM EDT
Market Cap8.08B
Revenue (ttm)3.48B
Net Income (ttm)327.09M
Shares Outn/a
EPS (ttm)0.52
PE Ratio24.70
Forward PEn/a
Dividend0.24 (1.83%)
Ex-Dividend DateSep 29, 2025
Volume100
Average Volume1,006
Open13.30
Previous Close13.30
Day's Range13.30 - 13.30
52-Week Range12.79 - 20.73
Beta0.82
RSI37.44
Earnings DateAug 6, 2025

About Sysmex

Sysmex Corporation engages in the development, manufacture, and sale of diagnostic instruments, reagents, and related software. It offers non-clinical blood testing and cell analysis for hematology, such as XN-V series, a software for laboratory animal corresponding to XN series fully automated hematology analyzers; XN-Series, a fully automated flagship hematology analyzers; and Automated hematology analyzer ProCyte Dx for Research applications, a housed in a compact body that simultaneously measures five types of leukocytes and reticulocyte co... [Read more]

Sector Healthcare
Founded 1968
Employees 10,533
Stock Exchange OTCMKTS
Ticker Symbol SSMXF
Full Company Profile

Financial Performance

In 2024, Sysmex's revenue was 508.64 billion, an increase of 10.21% compared to the previous year's 461.51 billion. Earnings were 53.67 billion, an increase of 8.12%.

Financial numbers in JPY Financial Statements

News

Sysmex reports FQ1 results

Sysmex (SSMXY) reports FQ1 results: Net sales down 5.6%, operating profit drops 36.5%, and attributable profit declines 58.7%.

20 days ago - Seeking Alpha

Sysmex reports 9M results

6 months ago - Seeking Alpha

Sysmex GAAP EPS of ¥41.70, revenue of ¥242.48B

Sysmex (SSMXY) reports a strong 1H performance with GAAP EPS of ¥41.70 and revenue of ¥242.48B, an impressive 14.0% increase year-over-year.

10 months ago - Seeking Alpha